Back to Top Skip to main content Skip to sub-navigation

DOD P&T Committee: 2017 Meetings

Nov. 15-16, 2017

Uniform Formulary Request for Quote Information
  • UF BPA & UF ADP RFQ Documents Posted: Aug. 21, 2017
  • Pre-Proposal Teleconference: Sept. 7, 2017 @ 12:00 p.m. Central 
  • Clinical/Cost Presentation Meeting Window: August - September 2017
  • UF BPA & UF ADP Quotes Due: Oct. 13, 2017 
  • P&T Committee Meeting: Nov. 15-16, 2017
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • Weight Loss Agents: Belviq, Belviq XR, Contrave, Qsymia, Saxenda, Xenical
  • Oncological Agents - Multiple Myeloma: Alkeran, Farydak, Melphalan, Ninlaro, Pomalyst, Revlimid, Thalomid
  • ArmonAir RespiClick
  • Baxdela
  • Benlysta
  • Bevyxxa
  • Cotempla XR ODT
  • Duzallo
  • Endari
  • Fiasp
  • Flolipid
  • Fycompa O/S
  • Gocovri
  • Haegarda
  • Idhifa
  • Mavyret
  • Nerlynx
  • Nityr
  • Symproic
  • Trelegy Ellipta
  • Tremfya
  • Verzenio
  • Vosevi


August 9-10, 2017

Uniform Formulary Request for Quote Information
  • UF BPA & UF ADP RFQ Documents Posted: May 5, 2017
  • Pre-Proposal Teleconference: May 18, 2017 @ 1200 Central 
  • Clinical/Cost Presentation Meeting Window: May - June, 2017
  • UF BPA & UF ADP Quotes Due: June 30, 2017 
  • P&T Committee Meeting: August 9-10, 2017
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • Antiretrovirals - Combinations: Atripla, Complera, Genvoya, Odefsey, Stribild, Triumeq
  • Antiretrovirals - Integrase Strand Transfer Inhibitors (INSTIs): Isentress, Tivicay, Vitekta
  • Antiretrovirals - Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTIs): Descovy, Emtriva, Trizivir, Truvada, Viread, Ziagen
  • Antiretrovirals - Other Agents: Aptivus, Crixivan, Edurant, Evotaz, Intelence, Invirase, Kaletra, Lexiva, Norvir, Prezcobix, Prezista, Rescriptor, Selzentry, Tybost, Viracept
  • Corticosteroids/Immune Modulators - Hereditary Angioedema Agents: Berinert, Cinryze, Firazyr, Kalbitor, Ruconest
  • Insulins - Basal: Basaglar Kwikpen U-100, Lantus, Lantus Solostar, Levemir, Levemir Flexpen, Levemir Flextouch, Toujeo Solostar, Tresiba Flextouch U-100, Tresiba Flextouch U-200
  • AirDuo RespiClick
  • Alunbrig
  • Ingrezza
  • Intrarosa
  • Jadenu Sprinkle
  • Kevzara
  • Kisqali Femara Co-Pack
  • Morphabond ER
  • Mydayis ER
  • Rydapt
  • Siliq
  • Syndros
  • Tymlos
  • Xadago
  • Xatmep
  • Zejula
 

May 10-11, 2017

Uniform Formulary Request for Quote Information
  • UF BPA & UF ADP RFQ Documents Posted: Feb. 15, 2017
  • Pre-Proposal Teleconference: February 21, 2017 @ 2:00 p.m. Central 
  • Clinical/Cost Presentation Meeting Window: March - April 2017
  • UF BPA & UF ADP Quotes Due: April 3, 2017 
  • P&T Committee Meeting: May 10-11, 2017
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • Overactive Bladder Agents: Gelnique, Myrbetriq, Oxytrol, Toviaz, Vesicare - Solicitation Cancelled
  • Ophthalmic-1 Agents: Bepreve, Emadine, Lastacaft, Pataday, Pazeo
  • Pulmonary Miscellaneous:  Esbriet, Ofev   
  • Arymo ER
  • Austedo
  • Dupixent
  • Emflaza
  • Eucrisa
  • Kisqali
  • Rhofade
  • Trulance
  • Xermelo
  • Xultophy
 

Feb. 8-9, 2017

  • Clinical/Cost Presentation Meeting Window: November - December 2016
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • Antibiotics - Tetracyclines
  • Hepatitis C Agents - Direct Acting Agents
  • Ophthalmic-1 Agents - Antihistamine Mast Cell Stabilizers: Solictation Cancelled
  • Adlyxin
  • Basaglar
  • BromSite
  • Rayaldee
  • Rubraca
  • Soliqua
  • Vemlidy
 
Last Updated: June 30, 2022

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.